If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Glucagon-like peptide-1 (GLP-1) is a well-known medication used by physicians to treat Type 2 diabetes. GLP-1 has also become ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily ...

Ozempic and other glucagon-like peptide-1 (GLP-1 ... recommended new criteria that look beyond BMI to also consider the location of fat and its effects on health and mobility. South Africa's ...